ZIOP - ZIOPHARM Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.70
+0.38 (+16.38%)
At close: 4:00PM EST

2.70 0.00 (0.00%)
After hours: 4:53PM EST

Stock chart is not supported by your current browser
Previous Close2.32
Open2.32
Bid2.64 x 4000
Ask2.70 x 34100
Day's Range2.31 - 2.79
52 Week Range1.90 - 5.25
Volume2,124,766
Avg. Volume1,277,723
Market Cap381.281M
Beta (3Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Trade prices are not sourced from all markets
  • Ziopharm Oncology (ZIOP) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 hours ago

    Ziopharm Oncology (ZIOP) Reports Q3 Loss, Lags Revenue Estimates

    Ziopharm (ZIOP) delivered earnings and revenue surprises of -18.18% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of ZIOP earnings conference call or presentation 12-Nov-18 1:00pm GMT

    Q3 2018 ZIOPHARM Oncology Inc Earnings Call

  • GlobeNewswireyesterday

    Ziopharm Oncology to Host Conference Call Today at 8 a.m.

    BOSTON, Nov. 12, 2018 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today will host a webcast and conference call today, Nov. 12, at 8 a.m. ET. On the call, management will.

  • GlobeNewswireyesterday

    Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer     

    Ziopharm Oncology, Inc., (ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with recurrent glioblastoma (rGBM). Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12) that activates the immune system and recruits cancer-fighting T cells into tumors.

  • GlobeNewswireyesterday

    Ziopharm Oncology Announces $50 Million Private Placement

    Ziopharm Oncology, Inc. (ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross proceeds to the Company of approximately $50 million, before deducting placement agent and other offering expenses. The private placement is being led by existing stockholder, MSD Partners, L.P. Other participants include Miller Value Partners, White Rock Capital Management and Level One Partners, LLC. Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Ziopharm will issue and sell 18,939,394 shares of common stock and warrants to purchase up to 18,939,394 additional shares of common stock at a per unit purchase price of $2.64.

  • Is ZIOPHARM Oncology Inc (NASDAQ:ZIOP) A Financially Sound Company?
    Simply Wall St.2 days ago

    Is ZIOPHARM Oncology Inc (NASDAQ:ZIOP) A Financially Sound Company?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like ZIOPHARM Oncology Inc (NASDAQ:ZIOP), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
    Zacks4 days ago

    Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

    Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

  • GlobeNewswire5 days ago

    Ziopharm Oncology Third Quarter 2018 Financial Results Conference Call Rescheduled to Nov. 12

    BOSTON, Nov. 08, 2018 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that it has rescheduled its quarterly conference call to Monday, Nov. 12, at 8 a.m. ET to.

  • GlobeNewswire6 days ago

    Ziopharm Oncology to Present at the Stifel 2018 Healthcare Conference on Nov. 14

    Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference in New York on Wednesday, Nov. 14, at 1:15 p.m. ET. Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective, and scalable immunotherapies for the treatment of multiple cancer types: Controlled IL-12 platform for Ad-RTS-hIL-12 plus veledimex and Sleeping Beauty platform for genetically modifying T cells. The Company is also advancing immunotherapies using the Sleeping Beauty platform, a non-viral approach to genetically modifying T cells with DNA plasmids to express chimeric antigen receptors (CAR) and T-cell receptors (TCR) to target specific antigens in blood cancers and neoantigens in solid tumors.

  • GlobeNewswire8 days ago

    Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced it will update data from its Phase 1 trial of Ad-RTS-hIL-12 plus veledimex, a gene therapy designed to control the expression of interleukin 12 (IL-12), a powerful cytokine that has demonstrated a targeted, anti-tumor immune response for the treatment of recurrent glioblastoma (rGBM), at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) in New Orleans. A poster entitled, “A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adults with recurrent glioblastoma: Dose determination with updated overall survival,” will be presented Friday, Nov. 16, at 7:30 p.m. CT.

  • GlobeNewswire13 days ago

    Ziopharm Oncology to Announce Third Quarter 2018 Financial Results, Host Conference Call Nov. 8

    The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective, and scalable immunotherapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • Ziopharm Oncology (ZIOP) Q3 Earnings Preview: What's Shaping Up?
    Zacks15 days ago

    Ziopharm Oncology (ZIOP) Q3 Earnings Preview: What's Shaping Up?

    Ziopharm (ZIOP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options
    Zacks18 days ago

    Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options

    Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

  • GlobeNewswire20 days ago

    Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire28 days ago

    Ziopharm Oncology Announces Changes to Board of Directors and Management Team

    BOSTON, Oct. 16, 2018 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced changes to its Board of Directors and management team. Ziopharm’s Chief Executive Officer Laurence Cooper, M.D., Ph.D, is appointed to the Board of Directors effective immediately, and Francois Lebel, M.D., is stepping down from his position as Chief Medical Officer (CMO) and Executive Vice President of Research & Development, effective Oct. 26.

  • GlobeNewswirelast month

    Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

    Ziopharm to Host Conference Call at 8 a.m. Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. With this exclusive license, Ziopharm now has full developmental control and exclusivity utilizing SB for TCRs targeted towards neoantigens and public antigens.

  • GlobeNewswire2 months ago

    Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • Should You Have ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) In Your Portfolio?
    Simply Wall St.2 months ago

    Should You Have ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) In Your Portfolio?

    If you own shares in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...

  • Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock?

    Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

  • GlobeNewswire2 months ago

    CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    In a release issued earlier today by Ziopharm Oncology, Inc. (ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued. Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 18. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 8. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ZIOP earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 ZIOPHARM Oncology Inc Earnings Call

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Ziopharm Oncology, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 14, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool3 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these fast-rising biotech stocks keep the momentum going?

  • Why Ziopharm Oncology Is Soaring 14% Today
    Motley Fool3 months ago

    Why Ziopharm Oncology Is Soaring 14% Today

    The company's second-quarter update is fueling optimism.